Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Published

Journal Article (Review)

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. A number of molecules, including ion channels and other proteins at the neuromuscular junction, may be targeted by autoantibodies leading to abnormal neuromuscular transmission. In approximately 85% of patients, autoantibodies, directed against the postsynaptic nicotinic acetylcholine receptor can be detected in the serum and confirm the diagnosis, but in general, do not precisely predict the degree of weakness or response to therapy. Antibodies to the muscle-specific tyrosine kinase are detected in approximately 50% of generalized myasthenia gravis patients who are seronegative for anti-acetylcholine receptor antibodies, and levels of anti-muscle-specific tyrosine kinase antibodies do appear to correlate with disease severity and treatment response. Antibodies to other muscle antigens may be found in the subsets of myasthenia gravis patients, potentially providing clinically useful diagnostic information, but their utility as relevant biomarkers (measures of disease state or response to treatment) is currently unclear.

Full Text

Duke Authors

Cited Authors

  • Meriggioli, MN; Sanders, DB

Published Date

  • July 2012

Published In

Volume / Issue

  • 8 / 5

Start / End Page

  • 427 - 438

PubMed ID

  • 22882218

Pubmed Central ID

  • 22882218

Electronic International Standard Serial Number (EISSN)

  • 1744-8409

Digital Object Identifier (DOI)

  • 10.1586/eci.12.34

Language

  • eng

Conference Location

  • England